VEGFA and renal cell carcinoma: An increased understanding of the oncogenesis of RCC has led to the development of several targeted treatment options, including tyrosine kinase inhibitors (TKIs), vascular endothelial growth factor (VEGF) targeted agents, and mammalian target of rapamycin (mTOR) inhibitors.